Celator Pharmaceuticals Company Profile (NASDAQ:CPXX)

About Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals logoCelator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CPXX
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $28.68
  • 200 Day Moving Avg: $12.63
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -91.64
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -75.03%
  • Return on Assets: -46.70%
Misc:
  • Beta: 7.09
 
Frequently Asked Questions for Celator Pharmaceuticals (NASDAQ:CPXX)

What is Celator Pharmaceuticals' stock symbol?

Celator Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPXX."

How were Celator Pharmaceuticals' earnings last quarter?

Celator Pharmaceuticals Inc (NASDAQ:CPXX) released its quarterly earnings data on Tuesday, May, 10th. The company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.01. View Celator Pharmaceuticals' Earnings History.

Who are some of Celator Pharmaceuticals' key competitors?

How do I buy Celator Pharmaceuticals stock?

Shares of Celator Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celator Pharmaceuticals' stock price today?

One share of Celator Pharmaceuticals stock can currently be purchased for approximately $30.24.


MarketBeat Community Rating for Celator Pharmaceuticals (NASDAQ CPXX)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  71 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about Celator Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Celator Pharmaceuticals (NASDAQ:CPXX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Celator Pharmaceuticals (NASDAQ:CPXX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
6/1/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Roth CapitalDowngradeBuy -> Neutral$30.25 -> $26.00N/AView Rating Details
3/15/2016HC WainwrightBoost Price TargetBuy$20.00N/AView Rating Details
10/30/2015FBR & CoReiterated RatingOutperformN/AView Rating Details
8/12/2015MLV & Co.Reiterated RatingBuy$6.00N/AView Rating Details
(Data available from 7/27/2015 forward)

Earnings

Earnings History for Celator Pharmaceuticals (NASDAQ:CPXX)
Earnings by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)
Earnings History by Quarter for Celator Pharmaceuticals (NASDAQ CPXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.15)($0.16)ViewListenView Earnings Details
3/21/2016Q4($0.12)($0.13)ViewN/AView Earnings Details
11/12/2015Q315($0.16)($0.15)ViewListenView Earnings Details
8/11/2015Q215($0.14)($0.15)ViewListenView Earnings Details
5/7/2015Q1 2015($0.14)($0.14)ViewN/AView Earnings Details
3/17/2015Q4 2014($0.16)($0.07)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.21)($0.21)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.20)($0.18)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.24)($0.16)ViewN/AView Earnings Details
3/24/2014Q4 13($0.15)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celator Pharmaceuticals (NASDAQ:CPXX)
Current Year EPS Consensus Estimate: $-0.60 EPS
Next Year EPS Consensus Estimate: $-0.33 EPS

Dividends

Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Celator Pharmaceuticals (NASDAQ:CPXX)
Insider Trades by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)
Institutional Ownership by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)
Insider Trades by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/3/2015Scott D MorensteinDirectorBuy5,000$1.87$9,350.00View SEC Filing  
10/6/2015Scott Thomas JacksonCEOBuy14,450$1.74$25,143.00View SEC Filing  
10/5/2015Fred M PowellCFOBuy13,700$1.78$24,386.00View SEC Filing  
10/1/2015Life Sciences Gp Ll Valence IIinsiderBuy12,200$1.64$20,008.00View SEC Filing  
11/18/2014Fred M PowellCFOBuy6,000$2.20$13,200.00View SEC Filing  
11/18/2014Michael R DoughertyDirectorBuy20,000$2.15$43,000.00View SEC Filing  
11/18/2014Scott Thomas JacksonCEOBuy10,000$2.20$22,000.00View SEC Filing  
5/15/2014Fred M PowellCFOBuy2,500$2.50$6,250.00View SEC Filing  
12/17/2013Fred M PowellCFOBuy2,500$3.50$8,750.00View SEC Filing  
12/17/2013Scott Thomas JacksonCEOBuy3,000$3.50$10,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Celator Pharmaceuticals (NASDAQ:CPXX)
Latest Headlines for Celator Pharmaceuticals (NASDAQ:CPXX)
Source:

Social

Chart

Celator Pharmaceuticals (CPXX) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by MarketBeat.com Staff